Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE

Jefferies Financial Group Inc. reduced its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 11.6% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 568,084 shares of the company’s stock after selling 74,273 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Apogee Therapeutics were worth $22,570,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after acquiring an additional 694 shares during the period. Millennium Management LLC grew its holdings in Apogee Therapeutics by 100.0% during the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after buying an additional 130,164 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Apogee Therapeutics during the second quarter valued at about $437,000. Lisanti Capital Growth LLC purchased a new stake in shares of Apogee Therapeutics in the second quarter worth about $800,000. Finally, Creative Planning bought a new position in shares of Apogee Therapeutics in the second quarter valued at approximately $392,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Insider Transactions at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 18,700 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total value of $1,455,608.00. Following the transaction, the insider owned 212,523 shares of the company’s stock, valued at $16,542,790.32. This represents a 8.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the sale, the director owned 298,647 shares in the company, valued at approximately $22,786,766.10. This trade represents a 85.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,839,700 shares of company stock valued at $140,130,083 in the last quarter. Insiders own 42.77% of the company’s stock.

Apogee Therapeutics Trading Up 3.0%

Shares of NASDAQ APGE opened at $73.05 on Monday. The business has a 50-day moving average of $72.38 and a 200-day moving average of $61.01. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of -17.31 and a beta of 1.39. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.02. On average, analysts predict that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on APGE shares. Wolfe Research started coverage on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. They set a “peer perform” rating for the company. Wedbush raised their price target on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Apogee Therapeutics in a report on Monday, February 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.92.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.